ALNAQ — Allena Pharmaceuticals Income Statement
0.000.00%
HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$1.68m
Annual income statement for Allena Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2017 December 31st | 2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 20.9 | 36.2 | 47.5 | 32 | 47.6 |
Operating Profit | -20.9 | -36.2 | -47.5 | -32 | -47.6 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -21.6 | -35.6 | -47.3 | -32.8 | -48.7 |
Provision for Income Taxes | |||||
Net Income After Taxes | -21.6 | -35.6 | -47.3 | -32.8 | -48.7 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -21.6 | -35.6 | -47.3 | -32.8 | -48.7 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -21.7 | -35.6 | -47.3 | -32.8 | -48.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.05 | -1.69 | -2.11 | -1.01 | -0.716 |